Company Overview
| Stock Name | 三生制葯 |
|---|---|
| Stock Code | 01530 |
| Company Full Name | 三生制葯 |
| Industry | 醫療保健 |
| Principal Activities | 主要於中國從事生物制藥產品的開發、生產、市場推廣及銷售。 |
| Listing Date | 2015-06-11 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國遼寧省沈陽市經濟技術開發區十號路1甲3號 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.3sbio.com |
| Share Registrar | |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 9.10 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 5.3% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 2,206,204,000 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 9.35 |
|---|---|
| First Day Open | HK$ 9.32 |
| First Day Change | 2.75% |
| First Day Volume | 233134000.0 |
| First Day Turnover | 2222160000.0 |
Use of Proceeds
| Use of Proceeds | 1、約45%，或約1,876.5百萬港元，將用于通過選擇性收購擴大我們重點治療領域的藥物產品組合； 2、約15%，或約625.5百萬港元，將用于透過聘額外銷售人員等方式加強我們產品的銷售及營銷； 3、約15%，或約625.5百萬港元，將用于為資本開支項目融資，以透過興建新生產線提高我們的產能； 4、約15%，或約625.5百萬港元，將用于為研發項目（包括內部研發項目及外部合作項目）融資； 5、約10%，或約417.0百萬港元，將用于補充我們的營運資金及作一般公司用途。 |
|---|
Underwriting Syndicate
Joint Sponsors (3)
CITIC Securities Corporate Finance (HK) Limited CE ABF671
高盛（亚洲）有限责任公司 CE ACC536
摩根士丹利亚洲有限公司 CE AAD291
Overall Coordinators (4)
摩根士丹利亚洲有限公司 CE AAD291
高盛（亚洲）有限责任公司 CE ACC536
中信里昂证券有限公司 CE AAB893
中国国际金融香港证券有限公司 CE AEN894
Joint Bookrunners (5)
摩根士丹利亚洲有限公司 CE AAD291
中信里昂证券有限公司 CE AAB893
高盛（亚洲）有限责任公司 CE ACC536
中国国际金融香港证券有限公司 CE AEN894
招商证券（香港）有限公司 CE AAI650
Joint Lead Managers (5)
摩根士丹利亚洲有限公司 CE AAD291
中信里昂证券有限公司 CE AAB893
高盛（亚洲）有限责任公司 CE ACC536
中国国际金融香港证券有限公司 CE AEN894
招商证券（香港）有限公司 CE AAI650
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | BlackRock Funds | 309,986,950 HKD | — | 1.41% | — | 6 months | 2015-12-11 |
| 2 | GIC Private Limited | 232,514,100 HKD | — | 1.05% | — | 6 months | 2015-12-11 |
| 3 | Lilly Asia Ventures Fund III, L.P. | 232,514,100 HKD | — | 1.05% | — | 6 months | 2015-12-11 |
| 4 | 工银瑞信资产管理(国际)有限公司 | 77,500,150 HKD | — | 0.35% | — | 6 months | 2015-12-11 |
| 5 | 新华资产管理(香港)有限公司 | 155,009,400 HKD | — | 0.70% | — | 6 months | 2015-12-11 |
| 6 | 中国人寿富兰克林资产管理有限公司 | 155,009,400 HKD | — | 0.70% | — | 6 months | 2015-12-11 |
Directors & Management
| Chairman | 婁競 |
|---|---|
| Company Secretary | 黎少娟 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 婁競及關連人士(21.62%);貝萊德(8.92%) |
|---|
